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Twenty years after their manufacture was
halted, polychlorinated biphenyls (PCBs)
remain a major environmental concern.
Standards often have been based on cancer
risk, yet before 1996 only commercial mix-
tures with 60% chlorine had been adequate-
ly tested. Different assumptions were made
for other mixtures: sometimes all PCB mix-
tures were considered carcinogenic and
sometimes only mixtures with high chlorine
content. A quantitative potency estimate
derived from mixtures with 60% chlorine
was applied to any PCB mixture regarded as
carcinogenic. The overlapping compositions
of different mixtures (Table 1) show the
problem with treating all mixtures the same
orcreating afalse dichotomy ofcarcinogenic
and noncarcinogenic mixtures.
New information is making possible a
more rational approach for distinguishing
among PCB mixtures. A recent study com-
pared the cancer potential of the commer-
cial mixtures Aroclors 1016, 1242, 1254,
and 1260 (1). Its results strengthen the case
that all PCB mixtures can cause cancer,
although different mixtures have different
potencies. Potency is also affected by the
environmental processes that alter PCB
mixtures. These processes diminish the sim-
ilarity of environmental mixtures to com-
mercial mixtures and can markedly increase
or decrease a mixture's toxicity.
As the Aroclor comparisons became
available, the EPAdeveloped a newapproach
to assessing the cancer risk from environ-
mental PCBs, considering both toxicity and
environmental processes (2). A range ofesti-
mates now characterizes the potency ofdif-
ferent mixtures, and information on envi-
ronmental processes is used to choose
appropriate values for representative classes
of environmental mixtures. There is also
guidance for assessing different exposure
pathways, less-than-lifetime and early-life
exposures, and mixtures containing dioxin-
like compounds. The use ofseveral kinds of
information fulfills the intent of the EPA's
proposed cancer guideline revisions (3) as
well as the instruction ofthe EPA's mixture
guidelines (4) to consider mixture composi-
tion. The new approach was reviewed by a
panel of independent experts on the car-
cinogenicity ofPCBs at a public peer review
workshop (5).
Summary of Cancer Evidence
for PCBs
Four commercial PCB mixtures, Aroclors
1016, 1242, 1254, and 1260, have been
tested in rats for their potential to cause
cancer. All mixtures induced liver tumors
when fed to female rats; Aroclor 1260 also
induced liver tumors in male rats (1).
Several ofthese tumors were hepatocholan-
giomas, a rare biliary tract tumor seldom
seen in control rats. These mixtures con-
tain overlapping groups ofcongeners that,
together, span the range ofcongeners most
often found in environmental mixtures.
Previously, lifetime dietary exposure to
commercial mixtures with 60% chlorine
induced liver tumors in three rat strains
(69). Although many ofthese tumors were
benign, sequential morphologic analyses
have demonstrated the eventual progression
ofthe benign liver lesions to malignant car-
cinomas (8). Commercial mixtures with
54% chlorine induced gastrointestinal
tumors (10-12). Less-than-lifetime dietary
exposure to commercial mixtures with
42-60% chlorine induced precancerous
liver lesions in rats and mice (13-18).
Epidemiologic studies have reported
similar tumor sites, although the same spe-
cific responsewas not seen across all studies.
Capacitor manufacturing workers exposed
to a series of commercial mixtures with
41-54% chlorine had increased mortality
from liver, gall bladder, and biliary tract
cancers (19), gastrointestinal tract cancers
(20), or malignant melanoma (21). An
analysis of these and a smaller study (22)
found the combined results significant for
liver, gall bladder, and biliary tract cancers
and for malignant melanoma (23). Earlier,
petrochemical refinery workers exposed to
Arodor 1254 and other chemicals had sig-
nificantly increased mortality from malig-
nant melanoma (24). More recently, elec-
tric utility workers exposed to PCBs had
significantly increased mortality from
malignant melanoma and brain cancer (25).
Recent case-control studies have found a
significant association between non-
Hodgkin's lymphoma and PCB concentra-
tions in adipose tissue (26) and serum (27).
In a general population, dietary consump-
tion of rice oil accidentally contaminated
with PCBs and chlorinated dibenzofurans,
which can be formed when PCBs are heated
above 270°C (28), was associated with sig-
nificantly increased mortality from liver
cancer and lung cancer (29).
Mechanistic studies have demonstrated
tumor-promoting activity in liver or lung
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which they are transported similarly
through the circulation (35), providing a
reasonable basis for expecting similar inter-
nal effects from different exposure routes.
Quantitatively, dermal exposure poses
lower risks because PCBs are substantially
but incompletely absorbed through the
skin (36-395.
Recent research is suggesting mecha-
nisms by which PCBs can contribute to
cancer at other sites. One experiment raises
concern for PCBs oflow chlorine content,
finding that dihydroxy metabolites of
PCBs with low chlorine content are acti-
vated to reactive intermediates that pro-
duce oxidative DNA damage (40). These
results provide a possible mechanism to
support the hypothesis that environmental
PCBs maycontribute to human breast can-
cer. Among the case-control studies of
non-Hodgkin's lymphoma, one study
Table 1.Typical composition ofsome commercial PCB mixtures
Aroclor Aroclor Aroclor Aroclor Aroclor
1016 1242 1248 1254 1260
Mono-CBs 2 1 - - -
Di-CBs 19 13 1 - -
Tri-CBs 57 45 21 1 -
Tetra-CBs 22 31 49 15 -
Penta-CBs - 10 27 53 12
Hexa-CBs - - 2 26 42
Hepta-CBs - - - 4 38
Octa-CBs - - - - 7
Nona-CBs - - - - 1
Deca-CB - - - -
PCDFs(ppm) ND 0.15-4.5 NR 0.8-5.6 0.8-5.6
Chlorine content 41 42 48 54 60
Production, 1957-1977 13 52 7 16 11
Abbreviations: PCB, polychlorinated biphenyl; CBs, chlorinated biphenyls; PCDFs, polychlorinated dibenzofurans; ND, not
detected; NR, notreported. Values shown are percent ofweight exceptwhere noted.
Data from Silberhorn etal. (30),the AgencyforToxic Substances and Disease Registry(35), and Brown et al. (43).
Table2. Reported composition ofcommercial mixturestested in the 1996 ratstudy
Mono-CBs
Di-CBs
Tri-CBs
Tetra-CBs
Penta-CBs
Hexa-CBs
Hepta-CBs
Octa-CBs
Nona-CBs
Deca-CB
PCB-77 (3,3',4,4'-TetraCB) (ppm)
PCB-126(3,3',4,4',5-PentaCB) (ppm)
PCB-169(3,3',4,4',5,5'-HexaCB) (ppm)
PCDFs (ppm)
TEQfrom PCBs(ppm)
TEQfrom PCDFs(ppm)
Aroclor
1016
0.83
17.64
54.98
25.84
0.69
0.01
66.0
0.95
0.0
0.05
0.14
0.002
Aroclor
1242
0.08
14.48
42.83
33.49
6.64
1.70
0.10
0.01
3340.0
44.0
0.0
2.2
8.1
0.1
Aroclor
1254
0.12
0.66
19.67
45.33
31.38
2.76
0.07
0.02
918.0
134.3
1.52
0.13
46.4
0.01
Aroclor
1260
0.15
0.48
2.41
11.96
39.28
36.38
7.67
1.59
0.07
31.0
0.0
0.0
5.5
7.1
0.08
found an association with both dioxinlike
and nondioxinlike congeners (26), and the
other found a multiplicative interaction
with seropositivity for the Epstein-Barr
virus early antigen (27). Because PCBs sup-
press the immune system and immunosup-
pression is an established risk factor for
non-Hodgkin's lymphoma, immune sys-
tem suppression may be a possible mecha-
nism for PCB-induced cancer. Other
research has associated both dioxinlike and
nondioxinlike congeners with toxicity due
to endocrinedisruption (41,42).
Differences in Cancer
Potential of Commercial PCB
Mixtures
The recent study comparingAroclors 1016,
1242, 1254, and 1260 (1) provides the best
information for distinguishing the cancer
potential of different mixtures.
Composition of the tested mixtures was
reported by homologues, plus three dioxin-
like congeners and total chlorinated diben-
zofurans (Table 2; compare with Table 1).
Prior to the study, the polychlorinated
dibenzofurans were removed from the
Aroclor 1254 fed to the rats because of
"unusually high" dibenzofuran concentra-
tions (43). Despite this pretreatment, the
resulting mixture was reported to have dou-
ble the usual dioxin toxic equivalents (43).
Concentrations of the three dioxinlike
congeners reported lie within the historical
range. One historical analysis found each of
these congeners below 500 ppm in each
Aroclor, except for 4500 ppm PCB-77 in
Aroclor 1242 and 500 ppm PCB-169 in
Aroclor 1260 (44). Another analysis found
2700-3300 ppm PCB-77 in Aroclor 1242,
300-2000 ppm PCB-77 in Aroclor 1254,
and up to 200 ppm PCB-126 in Aroclor
1254 (45). In sharp contrast, however, an
earlier analysis found 15,900 ppm PCB-
126 in Aroclor 1260 (35,46). These and
other variations provide evidence ofsignifi-
cant lot-to-lot variability among similar
mixtures. Striking lot-to-lot differences
have been found for Aroclors 1248 and
1254, due primarily to numerous con-
geners with four to six chlorines being cre-
ated and altered during the chlorination
process by which Ar6clors are manufac-
tured, and also to differences in the chlori-
nation processes that can be used (45).
These lot-to-lot differences highlight the
importance ofcharacterizing and reporting
mixture composition, both in toxicity test-
ing and in environmental samples.
In the recent cancerstudy (1), groups of
50 male or female Sprague-Dawley rats
were fed diets with 50, 100, or 200 ppm
Aroclor 1016; 50 or 100 ppm Aroclot
1242; or 25, 50, or 100 ppm Aroclor 1254
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fromArodor 1254 andsome congeners with
four to six chlorines: tetrachlorobiphenyl
congeners PCB-47, -49, -52, and -77
[International Union of Pure and Applied
Chemistry (IUPAC) numbering]; pen-
tachlorobiphenyl congeners PCB-105, -118,
and -126; and the hexachlorobiphenyl con-
gener PCB-153 (30). Toxicity ofsome con-
geners is correlated with induction ofmixed-
function oxidases: some congeners are phe-
nobarbital-type inducers, some are 3-methyl-
cholanthrene-type inducers, and some have
mixed inducing properties (31-33). The lat-
ter two groups most resemble chlorinated
dibenzo-p-dioxins and dibenzofurans in
structure and toxicity (33,34). These con-
geners contributing to cancer induction can
be present in mixtures with either high or
lowchlorine content (Table 1).
PCBs are absorbed through ingestion,
inhalation, and dermal exposure, after
Abbreviations: CBs, chlorinated biphenyls; PCB, polychlorinated biphenyl; PCDFs, polychlorinated dibenzofurans; TEQ,
toxic equivalent. Values shown are molecular percent exceptwhere noted.
Data from Brown etal.(43).
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or 1260. There were 100 controls of each
sex. Exposure began when the rats were 6-9
weeks old, and the animals were killed 104
weeks later. Complete histopathologic eval-
uations were done for control and high-
dose groups; for low- and mid-dose groups,
evaluations were done for liver, brain,
mammary gland, and male thyroid gland.
Statistically significant increased incidences
of liver tumors were found in female rats
for all Aroclors and in male rats for Aroclor
1260 (Table 3). Fewer than a quarter ofthe
tumors were malignant, but the proportion
of tumors that were malignant increased
with dose. In female rats, Aroclor 1254
appeared most potent, followed byArodors
1260 and 1242, with Aroclor 1016
markedly less potent. In male rats, only
Aroclor 1260 caused liver tumors.
To investigate tumor progression after
exposure stops, this same study exposed
groups of24 female rats for 52 weeks; expo-
sure was then discontinued for an addition-
al 52 weeks before the rats were killed. For
52 weeks exposure to Aroclors 1242 or
1254, tumor incidences were approximately
half those for 104 weeks exposure, that is,
nearly proportional to exposure duration.
In contrast, there were no tumors from 52
weeks exposure to Aroclor 1016, while for
Aroclor 1260 incidences were generally
greater than halfthose for 104 weeks expo-
sure (Table 4). For 100 ppm Aroclor 1260,
the incidence from 52 weeks exposure was
greater than that from 104 weeks, 71 and
48%, respectively.
Different patterns may hold for other
cancers. In the study just described (1), thy-
roid gland follicular cell adenomas or carci-
nomas were increased in males for all
Aroclors, and statistically significant trends
were noted forArodors 1242 and 1254. The
increases did not continue proportionately
above the lowest dose, and no thyroid trends
were apparent in females.
Modeling Results for
Commercial PCB Mixtures
Under the EPA's proposed cancer guideline
revisions (3), dose-response assessment first
considers developing a biologically based
model, that is, one whose mathematical
structure reflects the ascertained mode of
action and whose parameters are experi-
mentally measured. Few PCB congeners or
mixtures, however, have been tested to
measure the rate parameters that would be
used in a biologically based model.
Consequently, the information available at
this time is more suited to empirical mod-
eling, in which a flexible default model-
allowing either linearity or nonlinearity-is
fitted to describe tumor incidence as a
function ofdose in the experimental range.
The EPA's new assessment (2 fitted a
linear-quadratic dose-response model [that
is, a model ofthe form P(a) = 1-exp(-qld-
q2d2), where P(d) is the probability of
response at dose d, and ql and q2 are para-
meters] to the liver tumor incidences in
female Sprague-Dawley rats fed Aroclors
1016, 1242, 1254, or 1260 (Table 3).
Dose was expressed as a lifetime daily aver-
age, calculated from weekly body weight
measurements and food consumption esti-
mates. Doses were scaled to humans using
a factor based on the three-fourths power
of relative body weight (3). Response was
taken as the incidence of hepatocellular
adenomas or carcinomas. Combining ade-
nomas and carcinomas reflects the guid-
ance of the National Toxicology Program
(47) and the progression of hepatocellular
adenomas to carcinomas in female
Sprague-Dawley rats (8). To reflect lot-to-
lot variability among similar mixtures, the
Table3. Livertumor8 incidences from the 1996 ratstudy
Mixture Dose (ppm) Females Males
Aroclor 1260 Controlb 1/85(1%)* 7/98(7%)*
25 10/49(20%) 3/50(6%)
50 11/45(24%) 6/49(12%)
100 24/50(48%) 10/49 (20%)
Aroclor 1254 Controlb 1/85(1%)* 7/98(7%)
25 19/45(42%) 4/48(8%)
50 28/49(57%) 4/49(8%)
100 28/49(57%) 6/47(13%)
Aroclor 1242 Controlb 1/85(1%)* 7/98(7%)
50 11/49(24%) 1/50(2%)
100 15/45 (33%) 4/46(9%)
Aroclor 1016 Controlb 1/85(1%)* 7/98(7%)
50 1/48( 2%) 2/48(4%)
100 6/45(13%) 2V50(4%)
200 5/50(10%) 4/49(8%)
Data from Brunner etal. (1X, and reported bythe EPA(21.
fHepatocellular adenomas, carcinomas, cholangiomas, orcholangiocarcinomas in rats alive when thefirsttumor was observed.
bOne control group supported all experiments.
*Statistically significant(p<0.05) byCochran-Armitage trend test.
EPA also modeled earlier results in female
Sprague-Dawley rats fed from a different
lot ofAroclor 1260 (Table 5).
In the experimental range, the EPA
described the cancer potency of each mix-
ture by an estimated dose associated with
10% increased incidence (ED1O) and its
95% lower confidence bound (LED1O),
expressed as equivalent human doses
(Table 6). ED1os have been used both for
potency ranking and as a starting point for
low-dose extrapolation (48,49). The EPA
recently proposed using anLED1O for these
purposes, while inviting public comment
on the alternative of using 1% for tumor
responses (3).
To gauge the potential risk at environ-
mental exposure levels, the EPA extrapo-
lates to doses below the experimental
range. Extrapolation considers both linear
and nonlinear approaches, with a linear
default ifthere is not sufficient information
to support a sublinear model (3). This poli-
cy rests, in part, on some general considera-
tions. Low-dose linear models are appropri-
ate when a carcinogen acts in concert with
other exposures and processes leading to a
background incidence of cancer (50,51).
Table4. Livertumor8 incidences infemale ratsfrom
less-than-lifetime exposure
Dose
Mixture (ppm)
Aroclor 1260 Controld
25
50
100
Aroclor 1254 Controld
25
50
100
Aroclor 1242 Controld
50
100
Aroclor 1016 Controld
50
100
200
Less-than-
lifetimeb
exposure
1/85(1%)*
4/24(17%)
3/24(12%)
17/24(71%)
1/85(1%)*
5/24(21%)
7/24(29%)
6/24(25%)
1/85(1%)*
3/24(12%)
6/24(25%)
1/85(1%)
0/24(0%)
0/24(0%)
0/24(0%)
Lifetimec
exposure
1/85(1%)*
10/49(20%)
11/45(24%)
24/50(48%)
1/85 (1%)*
19/45(42%)
28/49(57%)
28/49(57%)
1/85(1%)*
11/49(22%)
15/45(33%)
1/85(1%)*
1/48(2%)
6/45(13%)
5/50(10%)
Data from Brunner et al. (1l, and reported bythe EPA12.
'Hepatocellular adenomas, carcinomas, cholangiomas, or cholan-
giocarcinomas.
bDosed for 52weeks and killed after 104weeks.
CDosedforand killed after 104weeks(fromTable3).
dOne control groupsupported all experiments.
*Statisticallysignificant(p<0.05) byCochran-Armitage trend test.
Table 5. Livertumora incidences from the Norback
ratstudy
Mixture Dose Females Males
Aroclor 1260 Control 1/45(2%)* 0/31 (0%)
100/50/0ppmb 41/46(89%) 5/40(12%)
Data from Norback andWeltman(8), reevaluated by
Moore etal. (9).
fHepatocellular adenomas or carcinomas.
bDosing was decreased after 16 and 24 months.
*Statisticallysignificant(p<0.05) by Fisher exacttest.
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Table 6. Human potency estimates (mg/kg/day)
derived from livertumors infemale Sprague-Dawley
rats
Mixture ED10 LED10 Reference
1016 2.4 1.4 (1)
1242 0.38 0.27 (1)
1254 0.086 0.067 (1)
1260 0.24 0.19 (1)
1260 0.062 0.046 (8)
Abbreviations: ED10, estmated dose associated with 10%
increased incidence; LED10, 95% lower confidence bound
on anED10.
Data from the EPA(2).
Moreover, even when the mode of action
indicates a nonlinear dose-response curve
in homogeneous animal populations, the
presence ofgenetic and lifestyle factors in a
heterogeneous human population tends to
make the population dose-response curve
more linear (51). This is because genetic
and lifestyle factors contribute to a wider
spread ofhuman variability, which extends
and straightens the dose-response curve
over a wider range. Although these consid-
erations provide a reasonable argument for
a model that is linear at low doses, the rela-
tion ofthe low-dose slope to one from the
experimental range is uncertain, an uncer-
tainty that increases with distance below
the experimental range.
For PCBs, genetic activity testing is
generally negative (35), raising the possibil-
ity of a sublinear dose-response curve. At
the low end of the experimental range
(25-50 ppm), however, dose-response
curves are not sublinear for Aroclors 1242,
1254, and 1260 (Table 3). Below the
experimental range, some PCB congeners
add to the considerable background of
human exposure to dioxinlike compounds
and augment processes associated with
dioxin toxicity, providing a linear compo-
nent to the dose-response curve. There is
also considerable background exposure to
nondioxinlike congeners, so additional
PCB exposure can augment other carcino-
genic processes that may be operating.
Lacking a dose range in which a sublinear
dose-response curve has been observed, the
information available at this time is more
suited to linearextrapolation.
Extrapolation below theED10 follows a
line with slope 0.10/ED10. An upper
bound on the slope is 0.10/LED1O. (Note
that slopes are inversely proportional to
ED1Os; high potency is indicated by high
slopes but low ED1Os.) Slope estimates can
be multiplied bylifetime average daily dose
estimates (in milligrams per kilogram body
weight per day) to obtain a plausible upper
bound on the increased cancer risk. The
slope estimates (Table 7) reflect experimen-
tal uncertainty and lot-to-lot variability of
Table 7. Human slope estimates (permg/kg/day)
Central
Mixture slope
1016 0.04
1242 0.3
1254 1.2
1260 0.4
1260 1.6
Data from the EPA(2).
Upper-bound
slope
0.07
0.4
1.5
0.5
2.2
Reference
(1)
(1)
(1)
(1)
(8)
commercial mixtures, but not human het-
erogeneity or differences between commer-
cial and environmental mixtures. Environ-
mental processes have profound effects that
can increase or decrease toxicity, so an
Arodor tested in the laboratory is not nec-
essarily the best surrogate for assessing that
Aroclor as altered in the environment.
Environmental Alteration of
PCB mixtures
In the environment, PCBs occur as mix-
tures whose compositions differ from the
commercial mixtures. This is because after
release into the environment, mixture com-
position changes over time through parti-
tioning, chemical transformation, and pref-
erential bioaccumulation.
Partitioning refers to processes by
which different fractions ofa mixture sepa-
rate into air, water, sediment, and soil.
PCBs adsorb to organic materials, sedi-
ments, and soils; adsorption tends to
increase with chlorine content ofthe PCBs
and organic content of the other material
(52). PCBs can volatilize or disperse as
aerosols, providing an effective means of
transport in the environment (52).
Congeners with low chlorine content tend
to be more volatile and also more soluble
in water (52). Vaporization rates and water
solubility ofdifferent Arodors and individ-
ual congeners vary over several orders of
magnitude (53,54).
Chemical transformation can occur
through biodegradation of PCB mixtures
in the environment. Anaerobic bacteria in
sediments can selectively remove chlorines
from meta andpara positions, appearing to
reduce the toxicity and bioaccumulation
potential of residues; the occurrence and
extent ofthese dechlorinations can be lim-
ited by sediment PCB concentrations
(55-57). Dechlorination is not synony-
mous with detoxication, as congeners hav-
ing carcinogenic activity can be formed
through dechlorination. Aerobic bacteria
can remove chlorines from PCBs with low
chlorine content and break open the carbon
rings through oxidation (55). PCBs with
higher chlorine content are extremely resis-
tant to oxidation and hydrolysis (52).
Photolysis can slowlybreakdown congeners
with high chlorine content (52). Overall,
however, dechlorination processes are slow,
and altered PCB mixtures persist in the
environment formanyyears.
Preferential bioaccumulation occurs in
living organisms. PCBs are highly soluble
in lipids and are absorbed by fish and other
animals. Rates ofmetabolism and elimina-
tion are slow and vary by congener (58).
Each species in the food chain retains per-
sistent congeners that prove resistant to
metabolism and elimination (59l). Bioaccu-
mulation through the food chain tends to
concentrate congeners of higher chlorine
content, producing residues that are con-
siderably different from the original
Aroclors (59-61). PCB residues in fish and
turtles, changed through environmental or
metabolic alteration, cannot be character-
ized byArodor 1242, 1248, 1254, or 1260
standards (60). Congener distributions in
several species, including humans, do not
resemble anyAroclor (33).
In humans, too, bioaccumulated PCBs
also appear to be more persistent in the
body (62). This is significant because in
animals bioaccumulated PCBs appear to be
more toxic than Aroclors (63). A study
comparing mink fed a given quantity of
Aroclor 1254 with mink fed Great Lakes
fish contaminated with one-third that
quantity of bioaccumulated PCBs (plus
other chemicals) found similar liver and
reproductive toxicity (64).
Assessing Risks from
Environmental PCBs
Consensus has emerged on the fallacy of
assessing environmental PCBs as if they
were Aroclors. Safe (34) wrote, "Regulatory
agencies and environmental scientists have
recognized that the composition of PCBs
in most environmental extracts does not
resemble the composition of the commer-
cial products." When assessing risks from
environmental PCBs, the EPA now consid-
ers how environmental processes alter mix-
ture composition (2).
Through partitioning, different por-
tions of a PCB mixture are encountered
through each exposure pathway. The mix-
ture fraction that adsorbs to sediment or
soil tends to be higher in chlorine content
and persistence than the original mixture;
it also tends to be less inclined to metabo-
lism and elimination and, thus, higher in
persistence and toxicity. (Persistence is not
synonymous with toxicity; however, in the
absence of testing of most congeners, it is
reasonable to assume some correlation
between persistence and toxicity.)
Consequently, ingesting contaminated sed-
iment or soil or inhaling contaminated
dust can pose relatively high risks. On the
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other hand, the mixture fraction that dis-
solves in water or evaporates into air tends
to be lower in chlorine content and persis-
tence, so risks from ingesting water-soluble
congeners or inhaling evaporated congeners
would tend to be lower, in the absence of
contaminated sediment or dust.
Preferential bioaccumulation can have
even more pronounced effects, as each
species in the food chain retains persistent
congeners that prove resistant to metabo-
lism and elimination. Bioaccumulated
PCBs appear to be more toxic than
Aroclors and more persistent in the body.
The Aroclors tested in laboratory animals
were not subject to prior selective retention
of persistent congeners through the food
chain. For exposure through the food
chain, therefore, risks can be higher than
those estimated in this assessment.
To reflect these environmental process-
es, the EPA nowprovides a tiered approach
that considers how partitioning and bioac-
cumulation affect each exposure pathway
or situation. Three tiers are provided:
* High risk and persistence (upper-bound
slope, 2 per mg/kg/day; central-estimate
slope, 1 per mg/kg/day). The highest slope
fromTable 7 is used forpathways inwhich
environmental processes tend to increase
risk: food chain exposure, sediment or soil
ingestion, dust or aerosol inhalation, expo-
sure to dioxinlike, tumor-promoting, or
persistent congeners, and early-life expo-
sure (allpathways and mixtures).
* Low risk and persistence (upper-bound
slope, 0.4 per mg/kg/day; central-estimate
slope, 0.3 per mg/kg/day). A lower slope
is appropriate for pathways inwhich envi-
ronmental processes tend to decrease risk:
ingestion ofwater-soluble congeners and
inhalation of evaporated congeners.
Dermal exposure is also included because
PCBs are incompletely absorbed through
the skin; however, if an internal dose has
been calculated by applying an absorption
factor to reduce the external dose, then
the highest slope would be used with the
internal dose estimate.
* Lowest risk and persistence (upper-bound
slope, 0.07 per mg/kg/day, central-estimate
slope, 0.04 per mg/kg/day). The lowest
slope from Table 7 is used when congener
orhomologueanalysesverifythatcongeners
with more than four chlorines comprise less
thanone-halfpercent oftotal PCBs.
The key finding supporting the lowest
tier is the lower potency ofAroclor 1016
compared with 1242 (Table 3). Though
these mixtures have similar chlorine con-
tent, Aroclor 1016 has virtually no con-
geners with more than four chlorines (Table
1). Thus, the lowest slope, derived from the
Aroclor 1016 study, is appropriate only for
mixtures free of congeners with more than
four chlorines.
The key assumption supporting lower-
tier risks for water-soluble or evaporated
congeners is that partitioning has reached
equilibrium. Congener or homologue
analysis ofenvironmental samples can veri-
fy whether equilibrium has been achieved.
For example, ifwater samples contain con-
geners ofhigh chlorine content, this could
indicate a continuing release into the envi-
ronment, a recent release without sufficient
time to partition as expected, a past release
with high chlorine content, or the presence
ofstirred-up sediment with adsorbed con-
geners ofhigh chlorine content. Judgment
should be used to choose a higher slope in
these situations.
Because the potency range for Aroclors
(Tables 6 and 7) can underestimate the
range for environmental mixtures, con-
gener analysis can be an important tool in
risk assessment, providing information on
the presence in environmental samples of
specific congeners that contribute to cancer
induction. When concentrations ofdioxin-
like congeners are available, risk estimates
can be refined using toxic equivalency fac-
tors developed for dioxinlike PCB con-
geners (65); the EPA provides an example
of this (2). Congener analysis can also
reveal composition changes for persistent
or tumor-promoting congeners that are not
dioxinlike. Among these, PCB-153
(2,2',4,4',5,5'-hexachlorobiphenyl) is of
particular interest, as it shows tumor pro-
moting activity, is highly persistent, and
comprises 12 and 21% ofPCBs in human
milkand fat, respectively (33).
Early-life exposure is treated with spe-
cial concern because of the potential for
higher exposure during pregnancy and
nursing (66,67) and the possibility of
greater perinatal sensitivity. Metabolic path-
ways are not fully developed in human
infants; for example, some nursing infants
receive a steroid in human milk that
inhibits the activity of glucuronyl trans-
ferase, reducing PCB metabolism and elim-
ination (68). In animals, Aroclor 1260
induced high incidences of liver tumors
when exposure began early in life and lasted
a short time (18). Perinatal exposure to
polybrominated biphenyls enhanced sus-
ceptibility to liver tumors in female rats also
exposed as adults and in male and female
mice not further exposed (69). It is, there-
fore, important to assess early-life exposure
through human milkandotherpathways.
For less-than-lifetime exposure, current
practice typicallyassumes thateffects arepro-
portional to exposure duration, yet there is
evidence that cancer risks can be higher for
persistent mixtures. Tumorincidences in rats
from 52 weeks exposure to Aroclor 1260
were comparable to those from lifetime
exposure (Table 4). This confirms earlier
findings that some PCBs persist in the body
and retain biological activity after exposure
stops (70). Thus, current practice can under-
estimate risks frompersistent mixtures.
Some Implications and
Research Needs
The EPA's new approach highlights how
environmental processes-partitioning,
chemical transformation, and preferential
bioaccumulation-alter the cancerpotential
ofenvironmental mixtures. Bioaccumulated
mixtures are of greatest concern because
they appear to be more toxic than commer-
cial mixtures and more persistent in the
body. Two highly exposed populations are
exposed to bioaccumulated mixtures. One
is nursing infants, for whom average intake
of total PCBs was estimated at 1.5-27
pg/kg/day (35), 3-11 pg/kg/day (46), or
2.1 pg/kg/day (71), compared to 0.2
pg/kg/day estimated for adults (46,71).
Dietary intake varies widely, often depend-
ing on proximity to where PCBs were
released into the environment (35,46). This
gives rise to another highly exposed popula-
tion: people who derive much oftheir diet
from local sources that happen to be conta-
minated, for example, subsistence anglers
and their families who frequently eat fish
from acontaminated source.
One prominent research need is a cancer
study comparing commercial and bioaccu-
mulated mixtures. The EPA's assessment
warns that risks from exposure through con-
taminated food can be underestimated, but
the extent is not quantified. Also needed is a
method for using lifetime studies to assess
risks from less-than-lifetime exposure to per-
sistent agents. The EPA's assessment warns
that assuming risk and exposure duration
are proportional can underestimate risks
from persistent mixtures, but the extent is
not quantified. For persistent agents, deliv-
ered dose mightbe a better dose metric than
thelifetime average dailydose.
The next question is how environmen-
tal processes alter the potential for non-
cancer toxicity and adverse ecological
effects. This requires a separate analysis, as
different sets ofcongeners may be associat-
ed with cancer and other effects.
Characterizing the effects ofenvironmental
processes can improve assessments of these
other effects. The same may be true when
assessing complex environmental mixtures
other than PCBs.
Additionally, the new assessment may
change thewayanalytical laboratories charac-
terize environmental samples. The prevailing
practice has been to describe environmental
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samples in terms ofAroclors, even though
environmental processes make the composi-
tion ofenvironmental mixtures considerably
different from Aroclor mixtures. Congener
and homologue analysis may become pre-
ferred for the ability to estimate the dioxin
toxic equivalence ofan environmental mix-
ture or verify whether PCBs found in water
or air are, as expected, oflow chlorine con-
tent and persistence. In particular, analysis
of dioxinlike congeners may be warranted
for exposure through contaminated food;
recently, PCB-126 (3,3',4,4',5-pen-
tachlorobiphenyl), the PCB congener with
the highest dioxin toxic equivalency factor
(65), was found in all of63 samples ofbeef
backfat (72).
Finally, the EPA's assessment proves
that good research can indeed improve risk
assessments. The recent study of four
Aroclors strengthened the case that all PCB
mixtures can cause cancer, resolving ques-
tions about the cancer hazard from differ-
ent PCB mixtures and providing key infor-
mation that now enables risk assessors to
quantify differences in cancer potency.
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